A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Eric Sievers, MD
Seagen Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Southern Cancer Center
Mobile, Alabama, United States
- Tower Cancer Research Foundation
Beverly Hills, California, United States
- Glendale Memorial Hospital
Glendale, California, United States
- Kenmar Research Institute
Los Angeles, California, United States
- University of California Los Angeles
Los Angeles, California, United States
- Bay Area Cancer Research Group
Pleasant Hill, California, United States
- University of Colorado Cancer Center
Aurora, Colorado, United States
- Lakeland Regional Cancer Center
Lakeland, Florida, United States
- H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
- Rush University Medical Center
Chicago, Illinois, United States
- Joliet Oncology-Hematology Associates
Joliet, Illinois, United States
- Michigan State University, Breslin Cancer Center
Lansing, Michigan, United States
- Billings Clinic Cancer Research
Billings, Montana, United States
- Northshore University Hospital, Monter Cancer Center
Lake Success, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Cleveland Clinic Foundation
Cleveland, Ohio, United States
- Western Pennsylvania Cancer Institute
Pittsburgh, Pennsylvania, United States
- Cancer Centers of the Carolinas
Greenville, South Carolina, United States
- University of Texas, Md Anderson Cancer Center
Houston, Texas, United States
- Gunderson Clinic
La Crosse, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2007
- Primary completion
- 31 Aug 2010
- Completion
- 31 Aug 2010
- Last update posted
- 7 Jan 2015
- Registered enrollment
- 211
- Registry id
- NCT00528333
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.